← Leaderboards
Margaret Khoury
University Of Southern California
$117,122
Attributed
$117,122
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $30.9K · FY2005–09$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$117,122 · 6
By mechanism
M01$117,122 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Frank D. Gilliland$43,061,630
- J.-H. James Ou$19,172,840
- Rob S McConnell$18,252,821
- Norah A. Terrault$8,729,722
- Andrea A. Kovacs$11,647,115
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthFundingScheduleSourcePowder Dose FormGrantAdolescentSafetyInfantInstitutionClinical ResearchMulticenter StudiesResearch PersonnelResourcesComputer Retrieval Of Information On Scientific Projects DatabaseCapsule (Pharmacologic)DoseChildDrug KineticsChildhoodAnti-Retroviral AgentsProtocols, TreatmentBms232632Formulations, Drug
Grant awards (8)
CLINICAL TRIAL: PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NO$26,473
M01 · FY2009 · RR · contact PI
PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASEO$4,975
M01 · FY2008 · RR · contact PI
PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASEO$30,946
M01 · FY2007 · RR · contact PI
PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASEO$12,111
M01 · FY2006 · RR · contact PI
AN OBSERVATIONAL STUDY OF THE RATE OF OPPORTUNISTIC INFECTION EVENTS IN HIV$6,060
M01 · FY2006 · RR · contact PI
PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASEO$19,362
M01 · FY2005 · RR
PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASEO$15,047
M01 · FY2004 · RR
An observational study of the rate of opportunistic$2,148
M01 · FY2004 · RR